|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1260132785 |
| 003 |
OCoLC |
| 005 |
20231120010553.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
210713s2021 ne o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d OPELS
|d OCLCO
|d UKAHL
|d OCLCF
|d UKMGB
|d CASUM
|d OCLCO
|d OCLCQ
|d OCLCO
|d K6U
|d SFB
|d OCLCA
|d OCLCQ
|d N$T
|d OCLCO
|
| 015 |
|
|
|a GBC192103
|2 bnb
|
| 016 |
7 |
|
|a 020219590
|2 Uk
|
| 020 |
|
|
|a 9780128199749
|q (electronic bk.)
|
| 020 |
|
|
|a 0128199741
|q (electronic bk.)
|
| 020 |
|
|
|a 9780128206843
|q (ePub ebook)
|
| 020 |
|
|
|a 0128206845
|
| 020 |
|
|
|z 9780128199732
|
| 020 |
|
|
|z 0128199733
|
| 035 |
|
|
|a (OCoLC)1260132785
|
| 050 |
|
4 |
|a QP383.7
|
| 082 |
0 |
4 |
|a 611.81
|2 23
|
| 245 |
0 |
0 |
|a Human hypothalamus :
|b neuropsychiatric disorders /
|c edited by Dick F. Swaab, Ruud M. Buijs, Felix Kreier, Paul J. Lucassen, Ahmad Salehi.
|
| 246 |
3 |
|
|a Neuropsychiatric disorders
|
| 260 |
|
|
|a Amsterdam :
|b Elsevier,
|c 2021.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Handbook of clinical neurology ;
|v v. 182
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Intro -- The Human Hypothalamus: Neuropsychiatric Disorders -- Copyright -- Foreword -- Preface -- The HCN volumes on the Human Hypothalamus -- The hypothalamus: Arbitrary borders -- References -- Contributors -- Contents -- Contents of related volumes -- Chapter 1: Introduction: The human hypothalamus and neuropsychiatric disorders -- Section 21Continued from the previous volume.: Trauma and Iatrogenic Disorders -- Section 22: Neurobehavioral Disorders -- Section 23: Epilepsy -- Section 24: Neurodegenerative Disorders -- Section 25: Olfactory System -- Section 26: Autonomic and Sleep Disorders -- Section 27: Addiction and Pain -- Section 28: Critical Care and Brain Death -- References -- Section 21: Trauma and iatrogenic disorders -- Chapter 2: Chronic traumatic encephalopathy and the nucleus basalis of Meynert -- Introduction -- Pathologic Features of CTE -- CTE Tau Pathological Staging -- Nucleus Basalis of Meynert in CTE -- Cholinergic Basal Forebrain Subfields -- Septal (Ch1) and diagonal band (Ch2-Ch3) cholinergic neurons -- Nucleus basalis (Ch4) cholinergic neurons -- Cholinergic nbM Dysfunction in CTE -- Tau NFT Pathology Within the nbM in CTE -- p62 profiles within the nbM in CTE -- Transactive response DNA-binding protein of 43 (TDP-43 or TARDBP) in the nbM in CTE -- Amyloid Pathology in the nbM in CTE -- nbM Cortical Cholinergic Disconnection in CTE -- White Matter Disruption of nbM Axons in CTE -- Transcript Expression in CTE -- Cholinergic Transcript Dysregulation in Tau-Containing nbM Neurons in CTE -- Chrnb2 dysregulation in nbM neurons in CTE -- Dopaminergic transcript dysregulation in tau positive nbM neurons in CTE -- Calcium transcript dysregulation in tau positive nbM neurons in CTE -- Endocytic transcript dysregulation in tau positive nbM neurons in CTE.
|
| 505 |
8 |
|
|a Cyclic adenosine monophosphate transcript dysregulation in tau positive nbM neurons in CTE -- Lissencephalic-1 transcript dysregulation in tau positive nbM neurons in CTE -- Chloride channel transcript dysregulation in tau positive nbM neurons in CTE -- Clinical Consequences of nbM Pathobiology in CTE -- Conclusions -- Acknowledgments -- References -- Section 22: Neurobehavioral disorders -- Chapter 3: Hypothalamic stress systems in mood disorders -- Stress System Dysfunction in Mood Disorders -- CRH and AVP -- Oxytocin -- Neuropeptides S and Y -- Orexins -- Translation of Neuropeptide Pharmacology Into Novel Medicines -- Corticotropin-releasing hormone (CRH)-Receptor type 1 (CRHR1) antagonists for treatment of major depr -- Vasopressin (AVP) 1B (V1b)-receptor antagonists for treatment of acute major depression -- Dual orexin receptor antagonists (DORAs) for treatment of insomnia and depression -- Conclusion -- References -- Chapter 4: Light therapy for mood disorders -- Introduction -- The beginning: Seasonal affective disorder -- Etiology of seasonal affective disorder -- Pathophysiology of (Peripartum) Mood Disorders -- The role of the hypothalamus-pituitary-adrenal axis -- The peripartum hypothalamus-pituitary-adrenal axis -- Fetal programming of the hypothalamus-pituitary-adrenal axis -- The role of the circadian rhythm -- The peripartum circadian rhythm -- Working Mechanisms of Light Therapy -- Clinical Studies of Light Therapy -- Light therapy for depression -- Light therapy for depression during pregnancy -- Light therapy for postpartum depression -- Light therapy for bipolar disorder -- Conclusions -- References -- Chapter 5: Neurobiology of peripartum mental illness -- Introduction to the Parental Brain -- Peripartum Mental Illness Occurs in One in Seven Women -- Neurobiology of Peripartum Mental Illness -- Peripartum anxiety disorders.
|
| 505 |
8 |
|
|a Peripartum depression -- Substance use disorder in the peripartum period -- Other peripartum mental illnesses -- Other Factors Influencing Peripartum Mental Illness -- Concluding Remarks and Future Directions -- Acknowledgments -- References -- Chapter 6: The hypothalamo-pituitary-adrenal axis and the autonomic nervous system in burnout -- Introduction -- The burnout concept -- Clinical burnout -- Hypothalamo-Pituitary-Adrenal Axis in Burnout -- Basal HPA axis activity -- Cortisol awakening response -- Diurnal HPA axis activity -- Hair cortisol -- Response to challenges -- Longitudinal studies -- Anabolic hormones -- Autonomic System in Burnout -- Resting autonomic activity -- Response to challenges -- Longitudinal studies -- Methodologic Aspects -- Summary -- References -- Chapter 7: Posterior hypothalamus as a target in the treatment of aggression: From lesioning to deep brain stimulation -- Introduction -- Clinical Correlates of Aggression -- Laboratory Experiences: Roots of Surgical Approach for Aggressive Disorders -- At the Dawn of Surgery for Aggressive Disorders: The Lesional Era -- A Step Into Brain Stimulation: The DBS Era -- From the Target to the Circuit -- Debate around the target: ``Posterior hypothalamus�� or ``A region posterior to the hypothala -- Circuit modulation -- Conclusions -- References -- Chapter 8: The implications of hypothalamic abnormalities for schizophrenia -- Introduction11Abbreviations used in the chapter are listed at the end of the chapter before References section. -- Hypothalamic Gross Anatomic Pathology in Schizophrenia -- Hypothalamic Cell Pathology in Schizophrenia -- Concentrations of Classical Neurotransmitters and Their Metabolites -- Changes in Hypothalamic Neurosecretory Neurons -- Alterations of Hypothalamic-Releasing and Inhibiting Factors Which Regulate Hormonal Axes.
|
| 505 |
8 |
|
|a Alteration of Peptide Hormones Regulating Food Intake, Appetite, and Satiety -- Alteration of Hypothalamic Opioid Peptides: POMC, Endorphins, and Enkephalins -- Alterations in the Expression of Susceptibility Genes for Schizophrenia -- Role of the Hypothalamus in Sleep Disturbances in Schizophrenia -- Disease-Related Neuroinflammatory and Neuroimmune Disturbances and the Impact of the Hypothalamus -- Conclusions -- References -- Chapter 9: The promiscuity of the oxytocin-vasopressin systems and their involvement in autism spectrum disorder -- Introduction: Oxytocin and Vasopressin Synthesis, Gene Structure, and Function -- Evolutionary History of Oxytocin and Vasopressin Ligands and Receptors -- Oxytocin and Vasopressin Ligand and Receptor Distribution in the Human and Mouse Brain -- Oxytocin and Vasopressin Regulate Social Behaviors -- Gene blockade and activation studies (knockout, pharmacological, chemogenetic, optogenetic) -- Oxytocin/vasopressin concentration and administration studies -- Epigenetic studies -- Single-nucleotide polymorphism (SNP) studies -- Oxytocinergic and Vasopressinergic Systems Are Impaired in ASD and Related Animal Models -- Nonhuman animal models -- Human patients -- Treatments for ASD Targeting the Oxytocinergic and Vasopressinergic Systems -- Treatments targeting the oxytocin system in adults -- In nonhuman animal models -- In human patients -- Treatments targeting the oxytocin system during development -- In nonhuman animal models -- In human patients -- Treatments targeting the vasopressin system -- In nonhuman animal models -- In human subjects -- Oxytocin and behavioral therapies -- Conclusion -- References -- Section 23: Epilepsy -- Chapter 10: Gelastic seizures and the hypothalamic hamartoma syndrome: Epileptogenesis beyond the lesion? -- Introduction.
|
| 505 |
8 |
|
|a MRI-Based Classification of HH With Regard to Clinical Phenotypes -- Seizure Semiology in Epilepsy With HH -- Gelastic seizures -- Dacrystic seizures -- Other seizure types -- Epilepsy with HH as a Model of Secondary Epileptogenesis -- Secondary epileptogenesis: Basis and principles -- Secondary epileptogenesis and hypothalamic kindling: Experimental data -- Intrinsic epileptogenicity of the HH: Arguments from invasive recordings -- Human data arguing for secondary epileptogenesis in HH -- Secondary Epileptogenesis and the Concept of Epileptogenic Networks -- Illustrative cases from Marseille series -- Conclusions -- References -- Chapter 11: The interactions between reproductive hormones and epilepsy -- Introduction -- The Effects of Hormones on Epilepsy -- Neuroactive properties of reproductive steroid hormones -- Estradiol -- Progesterone and its metabolites -- Androgens -- Effects of hormones on epilepsy-Clinical implications -- Puberty -- Catamenial epilepsy -- Changes in seizure frequency during pregnancy and effect of prior history of catamenial epilepsy -- Menopause -- Hormonal treatment -- The Effects of Epilepsy on Reproductive Endocrine Function -- The role of epilepsy in women -- The role of epilepsy in men -- Antiepileptic Drug-Related Mechanisms -- Reproductive endocrine effects of antiepileptic drugs in men -- Phenobarbital, phenytoin, and carbamazepine -- Valproate -- Oxcarbazepine -- Lamotrigine -- Other new antiepileptic drugs -- Reproductive endocrine effects of AEDs in male subjects with epilepsy during pubertal development -- Reproductive endocrine effects of antiepileptic drugs in women -- Phenobarbital, phenytoin, and carbamazepine -- Valproate -- Oxcarbazepine -- Lamotrigine -- Other new antiepileptic drugs -- Reversibility of the reproductive endocrine effects of antiepileptic drugs after discontinuation of the medication.
|
| 650 |
|
0 |
|a Hypothalamus.
|
| 650 |
|
0 |
|a Neurobehavioral disorders.
|
| 650 |
|
0 |
|a Human beings.
|
| 650 |
0 |
2 |
|a Humans
|0 (DNLM)D006801
|
| 650 |
1 |
2 |
|a Hypothalamus
|0 (DNLM)D007031
|
| 650 |
2 |
2 |
|a Hypothalamus
|x abnormalities
|0 (DNLM)D007031Q000002
|
| 650 |
|
2 |
|a Neurocognitive Disorders
|0 (DNLM)D019965
|
| 650 |
|
6 |
|a Hypothalamus.
|0 (CaQQLa)201-0023938
|
| 650 |
|
6 |
|a Troubles neurocognitifs.
|0 (CaQQLa)201-0304278
|
| 650 |
|
6 |
|a �Etres humains.
|0 (CaQQLa)201-0020070
|
| 650 |
|
7 |
|a Homo sapiens (species)
|2 aat
|0 (CStmoGRI)aat300265711
|
| 650 |
|
7 |
|a Hypothalamus
|2 fast
|0 (OCoLC)fst00966079
|
| 650 |
|
7 |
|a Neurobehavioral disorders
|2 fast
|0 (OCoLC)fst01036314
|
| 655 |
|
4 |
|a Internet Resources.
|
| 655 |
|
4 |
|a Index not Present.
|
| 700 |
1 |
|
|a Swaab, D. F.
|q (Dick Frans)
|
| 776 |
0 |
8 |
|i Print version:
|z 9780128206843
|
| 776 |
0 |
8 |
|i Print version:
|t Human hypothalamus.
|d Amsterdam : Elsevier, 2021
|z 0128199733
|z 9780128199732
|w (OCoLC)1240774544
|
| 776 |
0 |
8 |
|i Print version:
|t HUMAN HYPOTHALAMUS.
|d [S.l.] : ELSEVIER, 2021
|z 0128199733
|w (OCoLC)1240774544
|
| 830 |
|
0 |
|a Handbook of clinical neurology ;
|v v. 182.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/handbooks/00729752/182
|z Texto completo
|
